Verastem Oncology (VSTM) Stock Rallies On Collaboration Agreement with Amgen

Practice Stock Trading Your Capitals Is At Risk
Sam Boughedda
Updated: 20 Sep 2021

Shares of Verastem (NASDAQ: VSTM) are rallying premarket on Monday after it announced a clinical collaboration agreement with Amgen to evaluate the combination of VS-6766 with Amgen’s KRAS G12C inhibitor LUMAKRASTM (sotorasib).


VS-6766 is Verastem's investigational dual RAF/MEK inhibitor.

The Phase 1/2 trial will evaluate the safety, tolerability and efficacy of VS-6766 combined with LUMAKRASTM in patients with KRAS G12C-mutant NSCLC who have not previously been treated with a KRAS G12C inhibitor along with patients who have progressed on a KRAS G12C inhibitor. 

“We are pleased to partner with Amgen on this important research that could potentially expand treatment options for patients with KRAS G12C-mutant NSCLC,” said Brian Stuglik, CEO of Verastem Oncology. 

“This collaboration advances our strategy to fully explore the potential of VS-6766 as a backbone of therapy to treat RAS pathway-driven cancers.”

The company expects to begin the clinical trial by the end of this year. 

Verastem shares are currently up over 22.8% at $3.39 premarket on Monday. Its year-to-date gains stand at 29.58%.

Should You Invest in Verastem Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .